SAN DIEGO, Oct. 26, 2017 /Weed Wire/ – Medical Marijuana, Inc. (OTC: MJNA), the first-ever publicly traded cannabis company in the United States, announced today that subsidiary HempMeds® Mexico Executive Raúl Elizalde has been invited to speak on behalf of the family of companies, to the U.N. at the World Health Organization’s (WHO) International Drug Scheduling; Convention on Psychotropic Substances; Single Convention on Narcotic Drugs in Geneva, Switzerland, on Nov. 6, 2017.
Elizalde is a world-renowned medical cannabis advocate who started the Por Grace Foundation to further access to cannabidiol (CBD) by advocating for patients, hosting public forums, and meeting with government officials. Elizalde joined Mexico President Peña Nieto on stage in April, 2016, as the leader announced Mexico’s medical cannabis reform.
At the United Nations’ World Health Organization convention, Elizalde will speak to international leaders about his daughter’s personal experience with CBD and urge organization leaders to not consider CBD psychoactive and not schedule it as a drug. He will also emphasize the importance of the United States’ Ninth Circuit Court ruling that exempted the non-psychoactive parts of the hemp plant from the Controlled Substances Act. Most importantly, Elizalde will present research findings from studies conducted with children using CBD hemp oil products in Mexico by Dr. Saul Garza and Dr. Carlos Aguirre.
“I am honored to be a part of this incredible opportunity to be invited to speak in front of such a prestigious audience on a topic in which I am deeply passionate about,” said HempMeds® Mexico Executive Raúl Elizalde. “I would like to thank my many supporters who continue to aid my journey to further CBD reform worldwide.”
HempMeds Mexico is the first company to provide Mexican citizens with access to medical products derived from cannabis (THC-free hemp CBD) after the Health Department of Mexico, COFEPRIS, issued the country’s first-ever import permits for Real Scientific Hemp Oil-X™ RSHO-X™ in early 2016.
“We are honored and excited to speak to United Nations leaders on a global stage about CBD as a supplement aimed to maintain and improve the wellbeing of millions,” said Medical Marijuana, Inc. CEO Dr. Stuart Titus. “We hope to bring light to the many benefits of CBD and convince decision-makers that CBD in its natural botanical state, derived from hemp, should be classified as a supplement. We strongly believe that this botanical form adequately supports the optimal function of our body’s largest self-regulatory system, the Endogenous Cannabinoid System.”
To find out more or to make your CBD story a part of Raul’s journey, visit https://www.raulwho.co and follow HempMeds® on Facebook.
About HempMeds® Mexico
HempMeds® Mexico is a Mexico-based company that made history by being the first company to receive a COFEPRIS federal government import permit for the cannabis product RSHO-X™ for a medical indication. HempMeds® Mexico plans to work directly with the Mexican government to safely and legally provide access to CBD hemp oil products. For more information, please review the company’s website at: http://www.hempmeds.mx.
About Medical Marijuana, Inc.
We are a company of firsts®. Our mission is to be the premier cannabis and hemp industry innovators, leveraging our team of professionals to source, evaluate and purchase value-added companies and products, while allowing them to keep their integrity and entrepreneurial spirit. We strive to create awareness within our industry, develop environmentally-friendly, economically sustainable businesses, while increasing shareholder value. For details on Medical Marijuana, Inc.’s portfolio and investment companies, visit www.medicalmarijuanainc.com.
To see Medical Marijuana, Inc.’s video statement, click here.
Shareholders are also encouraged to visit the Medical Marijuana, Inc. Shop for discounted products.
FORWARD-LOOKING DISCLAIMER AND DISCLOSURES.
This press release may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and is subject to the Safe Harbor created by those sections. This material contains statements about expected future events and/or financial results that are forward-looking in nature and subject to risks and uncertainties. Such forward-looking statements by definition involve risks, uncertainties. The statements in this press release have not been evaluated by the FDA and are not intended to diagnose, treat or cure any disease. The Company does not sell or distribute any products that are in violation of the United States Controlled Substances Act. The Company does sell and distribute hemp-based products.